Drug Development and Clinical Trial Participation – A Webinar for the Rare Disease Community
CureDuchenne was pleased to host the “Drug Development and Clinical Trial Participation – A Webinar for the Rare Disease Community” on Friday, September 13. The webinar was an opportunity for parents to learn about the drug development process – from the pre-clinical phase to the clinical phase to the post approval phase and the regulatory process guiding these phases – from industry experts.
Click here to watch the recording of the webinar. You’ll be prompted to enter your name and email address to view the recording.
Click here for a glossary of terms
Our presenters were:
Carl Morris, Ph.D.
Director, Protein Therapeutics and Muscle Biology, Pfizer Rare Disease Research Unit
Lawrence Charnas M.D., Ph.D.
Director & Head, Discovery Medicine at Shire plc
Associate Director, Regulatory Affairs, Genzyme
The session was moderated by Michael Kelly, Ph.D., Chief Scientific Officer at CureDuchenne.